Advertisement

Clinical Epigenetics

, 10:36 | Cite as

Correction to: Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth

  • Yuzhu Wang
  • Tao He
  • James G. Herman
  • Enqiang Linghu
  • Yunsheng Yang
  • François Fuks
  • Fuyou Zhou
  • Linjie Song
  • Mingzhou Guo
Open Access
Correction
  • 325 Downloads

Correction

After publication of the original article [1], it came to the authors’ attention that a reference was omitted from the Background. The reference should have been inserted as [16] and is the following:

Vedeld HM, Andresen K, Eilertsen IA, Nesbakken A, Seruca R, Gladhaug IP, Thiis-Evensen E, Rognum TO, Boberg KM, Lind GE: The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers. Int J Cancer 2015, 136:844–853.

The last paragraph of the Background should have read as follows:

“Zinc finger protein 331 (ZNF331) was first identified from thyroid tumors [12]. It is also known as RITA (rearranged in thyroid adenoma), ZNF361, and ZNF463 [13]. The ZNF331 gene is located at chromosome 19q13.42, a region in which loss of heterozygosity (LOH) was detected in prostate cancer [14]. In our previous study, we found that the ZNF331 gene is frequently methylated in human esophageal squamous cell cancer (ESCC) and it serves as a tumor suppressor in ESCC [15]. It was reported that the high methylation frequency of ZNF331 was found in some types of gastrointestinal cancer including CRC [16]. But the function of ZNF331 in human CRC remains unclear. In this study, we analyzed the epigenetic regulation and the function of ZNF331 in human CRC.”

Reference

  1. 1.
    Wang, et al. Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth. Clin Epigenetics. 2017;9:115.  https://doi.org/10.1186/s13148-017-0417-4.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Yuzhu Wang
    • 1
    • 2
  • Tao He
    • 1
  • James G. Herman
    • 3
  • Enqiang Linghu
    • 1
  • Yunsheng Yang
    • 1
  • François Fuks
    • 4
  • Fuyou Zhou
    • 5
  • Linjie Song
    • 6
    • 7
  • Mingzhou Guo
    • 1
  1. 1.Department of Gastroenterology & HepatologyChinese PLA General HospitalBeijingChina
  2. 2.Department of Geriatric Digestive SystemChinese PLA Navy General HospitalBeijingChina
  3. 3.The Hillman Cancer CenterUniversity of Pittsburgh Cancer InstitutePittsburghUSA
  4. 4.Laboratory of Cancer EpigeneticsFree University of Brussels (U.L.B.)BrusselsBelgium
  5. 5.Department of Thoracic SurgeryAnyang Tumor HospitalAnyangChina
  6. 6.Department of General SurgeryChinese PLA General HospitalBeijingChina
  7. 7.Medical College of NanKai UniversityTianjinChina

Personalised recommendations